BBD BIOPHENIX SL

BBD BIOPHENIX SL specializes in biological assay services with a focused expertise in zebrafish-based toxicological and pharmacological testing for environmental and biomedical research. Their core capabilities center on high-throughput in vivo screening platforms, developmental toxicity assessment, and endpoint analysis using zebrafish models to evaluate chemical safety and biological activity. The contractor delivers standardized, reproducible assay protocols aligned with regulatory science frameworks, supporting risk assessment and drug discovery initiatives. Their technical proficiency includes automated imaging, phenotypic profiling, and data interpretation for neurotoxicity, cardiotoxicity, and endocrine disruption studies, positioning them as a niche provider of vertebrate-based testing services with high biological relevance. The contractor has demonstrated engagement with the Department of Health and Human Services, specifically supporting the National Institute of Environmental Health Sciences through task-order work focused on zebrafish assay services. This relationship indicates alignment with federal environmental health research priorities, including chemical screening under programs such as ToxCast and the Tox21 initiative. Their work supports evidence-based decision-making in public health and environmental regulation. Their primary NAICS classification under 541380 reflects a specialization in testing laboratories and services, particularly in preclinical biological testing. This places them within the broader life sciences contract research market, serving government-funded research institutions focused on environmental health, toxicology, and translational biology. They are positioned as a technical service provider rather than a broad-spectrum CRO. BBD BIOPHENIX SL operates as a small entity based in Donostia-San Sebastián, Spain, with no publicly disclosed federal certifications. Their geographic presence is international, serving U.S. federal research needs remotely or through collaborative arrangements. Their market positioning is defined by scientific precision in zebrafish model systems rather than scale or broad certification portfolios.